Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 521-530 of 2796 for

Edit search filters
  1. A Study to Evaluate Hepcidin Mimetic in Patients With Polycythemia Vera

    Scottsdale/Phoenix, AZ

  2. Study of Cabozantinib Combined With Atezolizumab Vs. Second Novel Hormonal Therapy in Subjects with Metastatic Castration-Resistant Prostate Cancer

    Rochester, MN

  3. Preoperative Radioactive Seed Localization of Nonpalpable Soft Tissue Masses

    Jacksonville, FL

  4. A Study to Evaluate A Resilient Living Program for Patients with Advancer Cancer and Their Caregivers

    Rochester, MN

  5. Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

    Rochester, MN

  6. Study of ISB 1342, a CD38/​CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

    Rochester, MN

  7. Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

    Rochester, MN, Jacksonville, FL

  8. Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

    Scottsdale/Phoenix, AZ, Rochester, MN

  9. A Study to Evaluate Durvalumab plus Topotecan or Lurbinectedin in Patients with Small Cell Lung Cancer

    Rochester, MN

  10. A Study Of 177Lu-FAP-2286 In Advanced Solid Tumors

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer